FGF23 and X-linked hypophosphatemia: An anti–FGF23 mAb (burosumab) approved for XLH treatment of affected children and adults, is not able to maintain serum 1,25D levels, which decline after initiation of therapy (43–45), similar to 1,25D levels in FGF23Ab-treated mice, which decrease by P75 (14).